Jeffreys Henry LLP, the cost-effective Auditor to LSE and AIM listed companies, has recently advised SkinBioTherapeutics Plc (“The Company”) on its £10.7 million AIM IPO.
SkinBioTherapeutics Plc is a life science company formed as a spin-out from the University of Manchester. The Company’s proprietary platform technology, SkinBiotix®, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
The IPO raised £4.5 million which will fund a whole host of work, including scale-up and manufacturing, formulation and testing in human volunteers.
Jeffreys Henry LLP acted as the Reporting Accountant in respect of the AIM IPO.
Ranked 12th place in the latest (May 2017) league table of Total AIM and Stock Market client, a team dedicated to working with listed companies and access to a global network, Jeffreys Henry LLP is a cost-effective Auditor for companies already listed, or considering listing, on the LSE, AIM, GEM, NEX or CSE markets.